Selv om der ikke var medtaget patienter under fem år i hovedundersøgelsen af Naglazyme, er det vigtigt, at de behandles, hvis de har en svær form for MPS VI.
Although patients under five years of age were not included in the main study of Naglazyme, it is important that they are treated if they have a severe form of MPS VI.